Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on March 12, 2019, with the report signed on March 14, 2019. The filing discloses the entry into a material definitive agreement regarding a private placement of equity securities.
Key Financial Metrics
- Private Placement Proceeds: $8,620,506 raised from the sale of 2,155,127 shares of common stock at $4.00 per share.
- Warrant Exercise Proceeds: $418,718 received from the exercise of certain warrants as of March 14, 2019.
- Total Combined Proceeds: $9,039,224.
- Debt and Liquidity: The filing does not provide specific data on existing debt levels, cash flow, or liquidity ratios outside of the new capital raised.
- Revenue and Profit: No revenue, profit, or margin data is provided in this filing.
Material Changes
The primary material change is the increase in equity capital and outstanding share count resulting from the private placement. The company sold 2,155,127 new shares to accredited investors. Additionally, the company incurred an obligation to file a registration statement (Form S-3 or S-1) within 45 calendar days of the closing to cover the resale of these shares, with all associated legal and filing expenses borne by the company.
Outlook, Risks, and Management Commentary
- Regulatory Obligations: The company must use commercially reasonable efforts to file and have declared effective a registration statement for the resale of the shares within 45 days of closing.
- Transaction Structure: The shares were sold unregistered under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
- Management Commentary: The filing references a press release (Exhibit 99.1) for further details but contains no forward-looking guidance or specific risk factors beyond standard transaction representations.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the status of the Form S-3 or S-1 registration statement filing within the 45-day window.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or liquidation preferences.
- Check the March 14, 2019 press release (Exhibit 99.1) for management's stated use of proceeds.
- Confirm the identity of the accredited investors if disclosed in subsequent filings.